Experience

Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling shareholder of 40,171,429 common shares for an aggregate amount of…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes issued by Change Healthcare Holdings, LLC and Change Healthcare…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have a 30-day option to purchase an additional 1,500,000 shares. The…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…

Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…

Davis Polk advised Roche Holdings, Inc. in connection with a cash tender offer for up to $250 million aggregate principal amount of its 7.00% notes due 2039. Headquartered in Basel,…

Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…

Davis Polk advised the sole placing agent in connection with the placing of 38,500,000 shares held by China Asset Management Co., Ltd. in Yestar International Holdings Company Limited for a…